Clinical Trials
1,282 trialsNCT01804686 2026-06-05
CAN3001
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT02981628 2026-06-05
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Children's Oncology Group
Phase 2 Recruiting
NCT03223610 2026-06-05
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
NCT03258567 2026-06-05
Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT03460977 2026-06-05
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Pfizer
Phase 1 Recruiting
NCT03922724 2026-06-05
Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT04747912 2026-06-05
Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)
University of Chicago
Phase 2 Recruiting
NCT04840602 2026-06-05
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT05421663 2026-06-05
A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
Janssen Research & Development, LLC
Phase 1/2 Recruiting
NCT05621291 2026-06-05
A Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymphoblastic Leu...
National Institutes of Health Clinical Center (CC)
Phase NA Recruiting
NCT05748171 2026-06-05
A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL
Pfizer
Phase 2 Recruiting
NCT05963074 2026-06-05
TAILOR
Janssen Research & Development, LLC
Phase 2 Recruiting
NCT06227026 2026-06-05
PRODIGY
University of Utah
Phase 1 Recruiting
NCT06284122 2026-06-05
MorningLyte
The Lymphoma Academic Research Organisation
Phase 3 Recruiting
NCT06643221 2026-06-05
Allo-X
University of Arizona
Phase EARLY_PHASE1 Recruiting
NCT06765317 2026-06-05
A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT06904066 2026-06-05
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT07137494 2026-06-05
A Study of MB-CART19.1 Cellular Therapy for People With Central Nervous System Lymphoma (CNSL)
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
NCT07194980 2026-06-05
Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Fred Hutchinson Cancer Center
Phase 2 Recruiting
NCT07278856 2026-06-05
Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas
City of Hope Medical Center
Phase 1 Recruiting
NCT07295951 2026-06-05
A Study of 14C-Bleximenib (Radiolabeled) in Participants With Acute Leukemia
Janssen Research & Development, LLC
Phase 1 Recruiting
NCT07302347 2026-06-05
MK-3475-G21
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT07308132 2026-06-05
A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies
Janssen Research & Development, LLC
Phase 1 Recruiting
NCT07328503 2026-06-05
CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT07570173 2026-06-05
MK-1045-005
Merck Sharp & Dohme LLC
Phase 2/3 Recruiting
NCT07628634 2026-06-05
Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors
University of California, Irvine
Phase EARLY_PHASE1 Recruiting
NCT07628738 2026-06-05
A Prospective Clinical Study on Reduced-intensity Radiotherapy for Stage I/II Low-risk Nasal-type NK/T-cell Lymphoma Achieving Complete Remission After Chemotherapy
Ruijin Hospital
Phase 2 Recruiting
NCT07630545 2026-06-05
A Phase I Study in Healthy Volunteers and Parkinson's Disease (PD) Patients.
Mission Therapeutics
Phase 1 Recruiting
NCT05139017 2026-06-04
waveLINE-003
Merck Sharp & Dohme LLC
Phase 2/3 Recruiting
NCT05751798 2026-06-04
Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas
OSE Immunotherapeutics
Phase 1/2 Recruiting
NCT05800210 2026-06-04
Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases
University of Florida
Phase 2 Recruiting
NCT06536049 2026-06-04
Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 1/2 Recruiting
NCT06943872 2026-06-04
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
BeOne Medicines
Phase 3 Recruiting
NCT06948786 2026-06-04
Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial
University of Washington
Phase 2 Recruiting
NCT07222345 2026-06-04
Feasibility of High Intensity Interval Training in Survivors of Childhood, Adolescent, and Young Adult Hodgkin Lymphoma
St. Jude Children's Research Hospital
Phase NA Recruiting
NCT07223021 2026-06-04
A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia
Memorial Sloan Kettering Cancer Center
Phase 3 Recruiting
NCT07226843 2026-06-04
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Eli Lilly and Company
Phase 1 Recruiting
NCT07228741 2026-06-04
Resistance Exercise and Incretin Mimetic for Cardiometabolic Health in Survivors of ALL With Obesity
St. Jude Children's Research Hospital
Phase 2 Recruiting
NCT07428707 2026-06-04
Immune Profiling of CLL/SLL Treated With First-Line Pirtobrutinib
National Institutes of Health Clinical Center (CC)
Phase EARLY_PHASE1 Recruiting
NCT07528352 2026-06-04
REBEL
University of Utah
Phase 1 Recruiting
NCT03739814 2026-06-03
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT04002947 2026-06-03
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT04195347 2026-06-03
Study of CM4620 to Reduce the Severity of Pancreatitis Due to Asparaginase
St. Jude Children's Research Hospital
Phase 1/2 Recruiting
NCT05006716 2026-06-03
CaDAnCe-101
BeOne Medicines
Phase 1/2 Recruiting
NCT05091424 2026-06-03
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
Hoffmann-La Roche
Phase 1 Recruiting
NCT05675410 2026-06-03
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
National Cancer Institute (NCI)
Phase 3 Recruiting
NCT05848687 2026-06-03
TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II
Stanford University
Phase 1/2 Recruiting
NCT06084936 2026-06-03
GLOBRYTE
Hoffmann-La Roche
Phase 3 Recruiting
NCT06124157 2026-06-03
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT06317662 2026-06-03
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
National Cancer Institute (NCI)
Phase 2 Recruiting